Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering Approach

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 19, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
December 08, 2019 16:00 ET | Source: uniQure Inc.

uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B

~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for...
December 02, 2019 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in December

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Dec. 02, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
November 06, 2019 09:16 ET | Source: uniQure Inc.

uniQure Announces Clinical Data Presentations at the 61st American Society of Hematology (ASH) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 06, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
November 05, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces the Allowance of New Patent Providing Further Protection of the Padua and Padua-Related Variants of Factor IX in Gene Therapy

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
November 01, 2019 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in November

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 01, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 31, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces Publication of Positive Interim Data from Phase IIb Clinical Trial of Etranacogene Dezaparvovec

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
October 28, 2019 07:00 ET | Source: uniQure Inc.

uniQure Announces Third Quarter 2019 Results and Highlights Recent Company Progress

~ Announced Completion of Full Patient Enrollment in HOPE-B Pivotal Study of Etranacogene Dezaparvovec ~ ~ Achieved Site Initiation and Began Patient Screening for Phase I/II Clinical Study of...
September 27, 2019 07:00 ET | Source: uniQure Inc.

uniQure to Participate in Multiple Upcoming Industry Conferences in October

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 27, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
September 05, 2019 20:39 ET | Source: uniQure Inc.

uniQure Announces Pricing of its Public Offering

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept. 05, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with...